Cell Death Dis. 2014 Mar 20;5:e1134.
|Source||Cell Death and Disease (2014) 5, e1134. Figure 5. ARRY-162 were obtained from AbMole BioScience, HongKong, China,|
|Method||Flow cytometric enumeration of propidium iodide staining|
|Cell Lines||U266, OPM2, RPMI8226, OCIMY1|
|Incubation Time||72 hours|
|Results||It was clear that LBH589 was found to be synergistic with MAPK and FAK inhibitors in all HMCL.|
|Cell lines||A549 and H460 human lung cancer cell lines|
|Preparation method||Cells were collected and seeded in 96-well plates at a density of 5×103 cells/well. Human lung cancer A549 cells or H460 cells were untreated or treated with indicated concentration of perifosine (0.3–10 μM), in the presence or absence of MEK-162 (1 μM); for 24 or 72 h, cell growth was tested by MTT assay.|
|Incubation time||24 or 72 h|
|Animal models||A549 lung cancer xenograft|
|Formulation||Formulated in 30% Captisol|
|Dosages||2.5 mg/kg, once daily|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 65 mg/mL|
Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo
Jianli Zhang,et,al. Tumor Biol. 2015;36:5699–5706.
|Related MEK Products|
trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division.
RO4987655 is an orally active and highly selective MEK inhibitor with an IC50 of 5.2 nM.
BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively.
LY2801653 is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase(Ki= 2 nM).
Refametinib (BAY 86-9766, RDEA119) is a potent, highly selective and ATP non-competitive inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.